Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular diseases

Histology and Histopathology

Volumn 15, Issue 2, 2000, Pages 557-571

  Rivard, A ^b   Andrés, Vicente ^a  

^a INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

^b NONE

Author keywords

Atherosclerosis; Cell cycle; Gene therapy; Restenosis; Smooth muscle cell

Indexed keywords

ANTIMITOTIC AGENT; GANCICLOVIR; GROWTH FACTOR; PROBUCOL; PROTEIN KINASE; TRANSCRIPTION FACTOR;

ATHEROSCLEROSIS; CELL AGING; CELL CYCLE; CELL HYPERPLASIA; CELL PROLIFERATION; CLINICAL TRIAL; DRUG MECHANISM; EXTRACELLULAR MATRIX; GENE THERAPY; GROWTH REGULATION; HEART INFARCTION; HUMAN; MECHANICAL STRESS; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL VASCULAR DISEASE; RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; STROKE; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARTERIOSCLEROSIS; CELL DIVISION; HUMANS; MUSCLE, SMOOTH, VASCULAR;

EID: 0034001995     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (230)

1. Abe J., Zhou W., Taguchi J., Takuwa N., Miki K., Okazaki H., Kurokawa K., Kumada M. and Takuwa Y. (1994). Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery. Biochem. Biophys. Res. Commun. 198, 16-24.
2. Aktas H., Cai H. and Cooper G.M. (1997). Ras links growth factor signaling to the cell cyle machinery via regulation of cyclin D1 and the cdk inhibitor p27KIP1. Mol. Cell. Biol. 17, 3850-3857.
3. American Heart Association (1996). "Heart and Stroke Facts: 1996 Statistical Supplement" (Dallas, TX).
4. Asada Y., Kisanuki A., Tsuneyoshi A., Marutsuka K., Hatakeyama K. and Sumiyoshi A. (1996). Effects of inflation pressure of balloon catheter on vascular injuries and subsequent development of intimal hyperplasia in rabbit aorta. Atherosclerosis 121, 45-53.
5. Asahara T., Bauters C., Pasture C., Kearney M., Rossow S., Bunting S., Ferrara N., Symes J.F. and Isner J.M. (1995). Local delivery of vascular endothelial growth factor accelerates reendothelization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 91, 2793-2801.
6. Asch A.S., Tepler J., Silbiger S. and Nachman R.L. (1991). Cellular attachment to thrombospondin: Cooperative interactions between receptor systems. J. Biol. Chem. 266, 1740-1745.
7. Assoian R.K. and Marcantonio E.E. (1996). The extracellular matrix as a cell cycle control element in atherosclerosis and restenosis. J. Clin. Invest. 98, 2436-2439.
8. Bagavandoss P. and Wilks J.W. (1990). Specific inhibition of endothelial cell proliferation by thrombospondin. Biochem. Biophys. Res. Commun. 170, 867-872.
9. Banai S., Wolf Y., Golomb G., Pearle A., Waltenberger J., Fishbein I., Schneider A., Gazit A., Perez L., Huber R., Lazarovichi G., Rabinovich L., Levitzki A. and Gertz S.D. (1998). PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation 97, 1960-1969.
10. Banskota N.K., Taub R., Zellner K. and King G.L. (1989). Insulin, insulin-like growth factor-1, and platelet-derived growth factor interact additively in the induction of the proto-oncogene c-myc and cellular proliferation in cultured bovine aortic smooth muscle cells. Mol. Endocrinol. 3, 1183-1190.
11. Bauters C. and Isner J.M. (1997). The biology of restenosis. Prog. Cardiovasc. Dis. 40, 107-116.
12. Bellas R.E., Lee J.S. and Sonenshein G.E. (1995). Expression of a constitutive NF-κB-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells. J. Clin. Invest. 96, 2521-2527.
13. Bendeck M.P., Zempo N., Clowes A.W., Gelardy R.E. and Reidy M.A. (1994). Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ. Res. 75, 539-545.
14. Bennett M.R., Anglin S., McEwan J.R., Jagoe R., Newby A.C. and Evan G.I. (1994). Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J. Clin. Invest. 93, 820-828.
15. Bennett M.R., Evan G.I. and Newby A.C. (1994). Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-γ, heparin, and cyclic nucleotide analogues and induces apoptosis. Circ. Res. 74, 525-536.
16. Bilato C. and Crow M.T. (1996). Atherosclerosis and the vascular biology of aging. Aging Clin. Exp. Res. 8, 221-234.
17. Bjornsson T.D., Dryjski M., Tluczek J., Mennie R., Ronan J., Mellin T.N. and Thomas K.A. (1991). Acidic fibroblast growth factor promotes vascular repair. Proc. Natl. Acad. Sci. USA 88, 8651-8655.
18. Botney M.D., Kaiser L.R., Cooper J.D., Mecham R.P., Parghi D., Roby J. and Parks W.C. (1992). Extracellular matrix protein gene expression in atherosclerotic hypertensive pulmonary arteries. Am. J. Pathol. 140, 357-364.
19. Brown K.E., Kindy M.S. and Sonenshein G.E. (1992). Expression of the c-myb proto-oncogene in bovine vascular smooth muscle cells. J. Biol. Chem. 267, 4625-4630.
20. Calara F., Ameli S., Hultgårdh-Nilsson A., Cercek B., Kupfer J., Hedin U., Forrester J., Shah P.K. and Nilsson J. (1996). Autocrine induction of DNA synthesis by mechanical injury of cultured smooth muscle cells. Potential role of FGF and PDGF. Arterioscler. Thromb. Vasc. Biol. 16, 187-193.
21. Califf R.M., Fortin D.F., Frid D.J., Harlan W.R., Ohman E.M., Bengtson J.R., Nelson C.L., Tcheng J.E., Mark D.B. and Stack R.S. (1991). Restenosis after coronary angioplasty: an overview. J. Am. Coll. Cardiol. 17, 2B-13B.
22. Campan M., Desgranges C., Gadeau A.-P., Millet D. and Belloc F. (1992). Cell cycle dependent gene expression in quiescent, stimulated, and asynchronously cycling arterial smooth muscle cells in culture. J. Cell. Physiol. 150, 493-500.
23. Campbell G.R. and Campbell J.H. (1990). The phenotypes of smooth muscle expressed in human atheroma. Ann. NY Acad. Sci. 598, 143-158.
24. Carmeliet P., Moons L., Herbert J.M., Crawley J., Lupu F., Lijnen R. and Coller D. (1997a). Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res 81, 829-39.
25. Carmeliet P., Moons L., Ploplis V., Plow E. and Collen D. (1997b). Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J. Clin. Invest. 99, 200-208.
26. Castellot J.J., Cochran D.L. and Karnovsky M.J. (1985). Effect of heparin on vascular smooth muscle cells. I. Cell metabolism. J. Cell. Physiol. 124, 21-28.
27. Cayatte A.J., Palacino J.J., Horten K. and Cohen R.A. (1994). Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler. Thromb. 14, 753-759.
28. Chang M.W., Barr E., Lu M.M., Barton K. and Leiden J.M. (1995a). Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J. Clin. Invest. 96, 2260-2268.
29. Chang M.W., Barr E., Seltzer J., Jiang Y., Nabel G.J., Nabel E.G., Parmacek M.S. and Leiden J.M. (1995b). Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 267, 518-522.
30. Kip1, an inhibitor of neointima formation in the rat carotid artery. J. Clin. Invest. 99, 2334-2341.
31. Chen D., Asahara T., Krasinski K., Witzenbichler B., Yang J., Magner M., Kearney M., Frazier W.A., Isner J.M. and Andres V. (1999a). Antibody blockade of thrombospondin accelerates reendothelialization and reduces neointima formation in balloon-injured rat carotid artery. Circulation 100, 849-854.
32. Chen D., Guo K., Yang J., Frazier W.A., Isner J.M. and Andres V. (1999b). Vascular smooth muscle cell growth arrest upon blockade of thrombospondin-1 requires p21Cip1/WAF1. Am. J. Physiol. 277, H1100-H1106.
33. Chen J., Jackson P.K., Kirschner M.W. and Dutta A. (1995). Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374, 386-388.
34. Chen L., Daum G., Forough R., Clowes M., Walter U. and Clowes A.W. (1998). Overexpression of human endothelial nitric oxide synthase in rat vascular smooth muscle cells and in balloon-injured carotid artery. Circ. Res. 82, 862-870.
35. Cheng G.C., Libby P., Grodzinsky A.J. and Lee R.T. (1996). Induction of DNA synthesis by a single transient mechanical stimulus of human vascular smooth muscle cells. Role of fibroblast growth factor-2. Circulation 93, 99-105.
36. Cheng G.C., Briggs W.H., Gerson D.S., Libby P., Grodzinsky A.J., Gray M.L. and Lee R.T. (1997). Mechanical strain tightly controls fibroblast growth factor-2 release from cultured vascular smooth muscle cells. Circ. Res. 80, 28-36.
37. Cheng L, Mantile G., Pauly R., Nater C., Felici A., Monticone R., Bilato C., Gluzband Y.A., Crow M.T., Stetler-Stevenson W. and Capogrossi M.C. (1998). Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation 98, 2195-201.
38. Choi E.T., Engel L., Callow A.D., Sun S., Trachtenberg J., Santoro S. and Ryan U.S. (1994). Inhibition of neointimal hyperplasia by blocking αvß3 integrin with a small peptide antagonist GpenGRGDSPCA. J. Vasc. Surg. 19, 125-134.
39. Clowes A., Reidy M. and Clowes M. (1983). Kinetics of cellular proliferation after arterial injury. I: smooth muscle cell growth in the absence of endothelium. Lab. Invest. 49, 327-333.
40. Clowes A.W. and Schwartz S.M. (1985). Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ. Res. 56, 139-145.
41. Clowes A.W., Clowes M.M., Au Y.P., Reidy M.A. and Belin D. (1990). Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ. Res. 67, 61-67.
42. Coats W.D. Jr., Whittaker P., Cheung D.T., Currier J.W., Han B. and Faxon D.P. (1997). Collagen content is significantly lower in restenotic versus nonrestenotic vessels after balloon angioplasty in the atherosclerotic rabbit model. Circulation 95, 1293-1300.
43. Condado J.A., Waksman R., Gurdiel O., Espinosa R., Gonzalez J., Burger B., Villoria G., Acquatella H., Cracker I.R., Seung K.B. and Liprie S.F. (1997). Long-term angiographic and clinical outcome after percutaneous transluminal coronary angioplasty and intracoronary radiation therapy in humans. Circulation 96, 727-732.
44. Cote G., Tardif J.C., Lesperance J., Lambert J., Bourassa M., Bonan R., Gosselin G., Joyal M., Tanguay J.F., Mattel S., Gallo R. and Crepeau J. (1999). Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group. Circulation 99, 30-35.
45. DeGregori J., Kowalik T. and Nevins J.R. (1995). Cellular targets for activation by the E2F1 transcription factor include DNA synthesis-and G1/S-regulatory genes. Mol. Cell. Biol. 15, 4215-4224.
46. Dixit V.M., Haverstick D.M., O'Rourke K.M., Hennessy S.W., Grant G.A., Santoro S.A. and Frazier W.A. (1985). Monoclonal antibodies against human thrombospondin inhibit platelet aggregation. Proc. Natl. Acad. Sci. USA 82, 3472-3476.
47. Elledge S.J. and Harper J.W. (1994). Cdk inhibitors: on the threshold of checkpoints and development. Curr. Opin. Cell Biol. 6, 847-852.
48. Ellis V. and Whawell S.A. (1997). Vascular smooth muscle cells potentiate plasmin generation by both urokinase and tissue plasminogen activator-dependent mechanisms: evidence for a specific tissue-type plasminogen activator receptor on these cells. Blood 90, 2312-2322.
49. Farnham P.J., Slansky J.E. and Kollmar R. (1993). The role of E2F in the mammalian cell cycle. Biochim. Biophys. Acta 1155, 125-131.
50. Ferns G.A., Raines E.W., Sprugel K.H., Motani A.S., Reidy M.A. and Ross R. (1991). Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 253, 1129-1132.
51. Ferns G.A.A., Foster L., Stewart-Lee A., Konneh M., Nourooz-Zadeh J. and Anggard E.E. (1992). Probucol inhibits neointimal thickening and macrophage accumulation after balloon injury in the cholesterol-fed rabbit. Proc. Natl. Acad. Sci. USA 89, 11312-11316.
52. Fischman D.L., Leon M.D., Baim D.S., Shatz R.A., Savage M.P., Penn I., Detre K., Veltri L., Ricci D., Nobuyshi M., Cleman M., Heuser R., Almond D., Teirstein P.S., Fish R.D., Colombo A., Brinker J., Moses J., Shaknovich A., Hirshfeld J., Bailey S., Ellis S., Rake R. and Goldberg S. (1994). A randomized comparison of coronary-stent-placement and balloon angioplasty in the treatment of coronary artery disease. N. Engl. J. Med. 331, 469-501.
53. Flores-Rozas H., Kelman Z., Dean F.B., Pan Z., Harper J.W., Elledge S.J., O'Donnell M. and Hurwitz J. (1994). Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase δ holoenzyme. Proc. Natl. Acad. Sci. USA 91, 8655-8659.
54. Folkow B. and Svanborg A. (1993). Physiology of cardiovascular aging. Physiol. Rev. 73, 725-764.
55. Franklin S.M. and Faxon D.P. (1993). Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials. Coronary Artery Dis. 4, 232-242.
56. Frazier W.A. (1991). Thrombospondins. Curr Opin. Cell. Biol. 3, 792-799.
57. Frimerman A., Welch P.J., Jin X., Eigler N., Yei S., Forrester J., Honda H., Makkar R., Barber J. and Litvack F. (1999). Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model. Circulation 99, 697-703.
58. Fukumoto S., Nishizawa Y., Hosoi M., Koma H., Yamakawa K., Ohno S. and Morii H. (1997). Protein kinase C δ inhibits the proliferation of vascular smooth muscle cells by suppressing G1 cyclin expression. J. Biol. Chem. 272, 13816-13822.
59. Fuster V., Badimón L., Badimón J.J. and Chesebro J.H. (1992). The pathogenesis of coronary artery disease and the acute coronary syndromes. N. Engl. J. Med. 236, 242-250.
60. Galis S., Sukhova G.K., Lark M.V. and Libby P. (1994). Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94, 2493-2503.
61. Geary R.L., Williams U.K., Golden D., Brown D.G., Benjamin M.E. and Adams M.R. (1996). Time course of cellular proliferation, intimal hyperplasia, and remodeling following angioplasty in monkeys with established atherosclerosis. A nonhuman primate model of restenosis. Arterioscler. Thromb. Vasc. Biol. 16, 34-43.
62. Good D.J., Polverini P.J., Rastinejad F., Le Beau M.M., Lemons R.S., Frazier W.A. and Bouck N.P. (1990). A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA 87, 6624-6628.
63. Gorski D.H. and Walsh K. (1995). Mitogen-responsive nuclear factors that mediate growth control signals in vascular myocytes. Cardiovasc. Res. 30, 585-592.
64. Gorski D.H., LePage D.F., Patel C.V., Copeland N.G., Jenkins N.A. and Walsh K. (1993). Molecular cloning of a diverged homeobox gene that is rapidly down-regulated during the G0/G1 transition in vascular smooth muscle cells. Mol. Cell. Biol. 13, 3722-3733.
65. Graña X. and Reddy E.P. (1995). Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11, 211-219.
66. Guadagno T.M. and Newport J.W. (1996). Cdk2 kinase is required for entry into mitosis as a positive regulator of cdc2-cyclin B kinase activity. Cell 84, 73-82.
67. Guevara N.V., Kim H.S., Antonova E.I. and Chan L. (1999). The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat. Med. 5, 335-339.
68. Guo K., Andres V. and Walsh K. (1998). Nitric oxide-induced downregulation of cdk2 activity and cyclin A gene transcription in vascular smooth muscle cells. Circulation 20, 2066-2072.
69. Hamon M., Vallet B., Bauters C., Wernet N., McFadden E.P., Lablanche J., Dupuis B. and Bertrand M.E. (1994). Long-term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependent acetylcholine-induced relaxation after arterial injury. Circulation 90, 1357-1362.
70. Hanke H., Strohschneider T., Oberhoff M., Betz E. and Karsch K.R. (1990). Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. Circ. Res. 67, 651-659.
71. Hariri R., Alonso D.R., Hajjar D.P., Coletti D. and Weksler M.E. (1986). Aging and atherosclerosis. I. Development of myointimal hyperplasia following endothelial injury. J. Exp. Med. 164, 1171-1178.
72. Hariri R.J., Hajjar D.P., Coletti D., Alonso D.R., Wekser M.E. and Rabellino E. (1988). Aging and atherosclerosis. Cell cycle kinetics of young and old arterial smooth muscle cells. Am. J. Pathol. 131, 132-136.
73. Hart C.E., Kraiss L.W., Vergel S., Gilbertson D., Kenagy R., Kirkman T., Crandall D.L., Tickle S., Finney H., Yarranton G. and Clowes A.W. (1999). PDGFbeta receptor blockade inhibits intimal hyperplasia in the baboon. Circulation 99, 564-569.
74. Heichman K.A. and Roberts J.M. (1994). Rules to replicate by. Cell 79, 557-562.
75. Helin K. and Harlow E. (1993). The retinoblastoma protein as a transcriptional represser. Trends Cell Biol. 3, 43-46.
76. Herbert J.M., Lamarche I., Prabonnaud V., Dol F. and Gauthier T. (1994). Tissue-type plasminogen activator is a potent mitogen for human aortic smooth muscle cells. J. Biol. Chem. 269, 3076-3080.
77. Hishikawa K., Nakaki T., Marumo T., Suzuki H., Kato R. and Saruta T. (1994). Pressure promotes DNA synthesis in rat cultured vascular smooth muscle cells. J. Clin. Invest. 93, 1975-1980.
78. Hoshiga M., Alpers C.E., Smith L.L., Giachelli C.M. and Schwartz S.M. (1995). Alpha-v beta-3 integrin expression in normal and atherosclerotic artery. Circ Res 77, 1129-1135.
79. Hu Y., Cheng L., Hochleitner B.W. and Xu Q. (1997). Activation of mitogen-activated protein kinases (ERK/JNK) and AP-1 transcription factor in rat carotid arteries after balloon injury. Arterioscler. Thromb. Vasc. Biol. 17, 2808-2816.
80. Hultgårh-Nilsson A., Krondahl U., Querol-Ferrer V. and Rigertz N.R. (1991). Differences in growth factor response in smooth muscle cells isolated from adult and neonatal rats. Differentiation 47, 99-105.
81. Hunter T. and Pines J. (1994). Cyclins and cancer: cyclin D and cdk inhibitors come on age. Cell 79, 573-582.
82. Hynes R.O. (1992). Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69, 11-25.
83. Indolfi C., Avvedimento E.V., Rapacciuolo A., Di Lorenzo E., Esposito G., Stabile E., Feliciello A., Mele E., Giuliano P., Condorelli G. and Chiariello M. (1995a). Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nature Med. 1, 541-545.
84. Indolfi C., Esposito G., DiLorenzo E., Rapacciuolo A., Feliciello A., Porcellini A., Avvedimento V.E., Condorelli M. and Chiariello M. (1995b). Smooth muscle cell proliferation is proportional to the degree of balloon injury in a rat model of angioplasty. Circulation 92, 1230-1235.
85. Iruela-Arispe M.L., Bornstein P. and Sage H. (1991). Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc. Natl. Acad. Sci. USA 88, 5026-5030.
86. Sdi1/Cip1/Waf1 by nitric oxide-generating vasodilator in vascular smooth muscle cells. J. Biol. Chem. 271, 10050-10057.
87. Jackson C.L., Raines E.W., Ross R. and Reidy M.A. (1993). Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscler. Thromb. 13, 1218-1226.
88. Jaffe E.A., Ruggiero J.T. and Falcone D.J. (1985). Monocytes and macrophages synthesize and secrete thrombospondin. Blood 65, 79-84.
89. Jaffe E.A., Ruggiero J.T., Leung L.K., Doyle M.J., McKeown-Longo P.J. and Mosher D.F. (1983). Cultured human fibroblasts synthesize and secrete thrombospondin and incorporate it into extracellular matrix. Proc. Natl. Acad. Sci. USA 80, 998-1002.
90. Janssens S., Flaherty D., Nong Z., Varenne O., van Pelt N., Haustermans C., Zoldhelyi P., Gerard R. and Collen D. (1998). Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation 97, 1274-1281.
91. Kannel W. and Gordon T. (1980). Cardiovascular risk factors in the aged: the Framingham study. In Epidemiology of aging. Haynes S. and Feinleib M. (eds). NIH. Bethesda. pp 65-98.
92. Karim M.A., Miller D.D., Farrar M.A., Elefheriades E., Reddy B.H., Brelan C.M. and Samarel A.M. (1995). Histomorphometric and biochemical correlates of arterial procollagen gene expression during vascular repair after experimental angioplasty. Circulation 91, 2049-2057.
93. Kearney M., Pieczek A., Haley L., Losordo D.W., Andrés V., Schainfield R., Rosenfield R. and Isner J.M. (1997). Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation 95, 1998-2002.
94. Kerkhoff E. and Rapp U.R. (1997). Induction of cell proliferation in quiescent NIH 3T3 cells by oncogenic c-Raf-1. Mol. Cell. Biol. 17, 2576-2586.
95. Kindy M.S. and Sonenshein G.E. (1986). Regulation of oncogene expression in cultured aortic smooth muscle cells: post-transcriptional control of c-myc mRNA. J. Biol. Chem. 261, 12865-12868.
96. King R.W., Jackson P.K. and Kirschner M.W. (1994). Mitosis in transition. Cell 79, 563-571.
97. Koyama H., Raines E.W., Bornfeldt K.E., Roberts J.M. and Ross R. (1996). Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of cdk2 inhibitors. Cell 87, 1069-1078.
98. Lai K., Lee W.-S., Jain M.K., Lee M.-E. and Haber E. (1996). Mitogen-activated protein kinase phosphatase-1 in rat arterial smooth muscle cell proliferation. J. Clin. Invest. 98, 1560-1567.
99. Lawler J., Slayter H.S. and Coligan J.E. (1978). Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. J. Biol. Chem. 253, 8609-8616.
100. Le Tourneau T., Van Belle E., Corseaux D., Ballet B., Lebuffe G., Dupuis B., Lablanche J.M., McFadden E., Bauters C. and Bertrand M.E. (1999). Role of nitric oxide in restenosis after experimental balloon angioplasty in the hypercholesterolemic rabbit: effects on neointimal hyperplasia and vascular remodeling. J. Am. Coll. Cardiol. 33, 876-882.
101. Leone G., DeGregori J., Sears R., Jakoi L. and Nevins J.R. (1997). Myc and Ras collaborate in inducing accumulation of active cyclin E/cdk2 and E2F. Nature 387, 422-426.
102. Liau G., Winkles J.A., Cannon M.S., Kuo L. and Chilian W.M. (1993). Dietary-induced atherosclerotic lesions have increased levels of acidic FGF mRNA and altered cytoskeletal and extracellular matrix mRNA expression. J. Vasc. Res. 30, 327-332.
103. Libby P. and Tanaka H. (1997). The molecular basis of restenosis. Prog. Cardiovasc. Dis. 40, 97-106.
104. Libby P., Schwartz D., Brogi E., Tanaka H. and Clinton S.K. (1992). A cascade model for restenosis: a special case of atherosclerosis progression. Circulation 86 (Supplement), III47-III52.
105. Lille S., Daum G., Clowes M.M. and Clowes A.W. (1997). The regulation of p42/p44 mitogen-activated protein kinases in the injured rat carotid artery. J. Surg. Res. 70, 178-186.
106. Lindner V. and Reidy M.A. (1991). Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA. 88, 3739-3743.
107. Lloyd A.C., Obermüller F., Staddon S., Barth C.F., McMahon M. and Land H. (1997). Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev. 11, 663-677.
108. Cip1. Nature 375, 159-161.
109. Lupu F., Heim D.A., Bachmann F., Hurni M., Kakkar V.V. and Kruithof E.K. (1995). Plasminogen activator expression in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 15, 1444-1455.
110. Lyall F., Deehan M.R., Greer I.A., Boswell F., Brown W.C. and McInnes G.T. (1994). Mechanical stretch increases proto-oncogene expression and phosphoinositide turnover in vascular smooth muscle cells. J. Hypertens. 12, 1139-1145.
111. Maillard L., Van Belle E., Smith R.C., Le Roux A., Denèfle P., Steg G., Barry J.J., Branellec D., Isner J.M. and Walsh K. (1997). Percutaneous delivery of the gax gene inhibits vessel stenosis in a rabbit model of balloon angioplasty. Cardiovasc. Res. 35, 536-546.
112. Majack R.A. (1987). Beta-type transforming growth factor specifies organizational behavior in vascular smooth muscle cell cultures. J. Cell Biol. 105, 465-471.
113. Majack R.A., Cook S.C. and Bornstein P. (1986). Control of smooth muscle cell growth by components of the extracellular matrix: Autocrine role for thrombospondin. Proc. Natl. Acad. Sci. USA 83, 9050-9054.
114. Majack R.A., Majesky M.W. and Goodman L.V. (1990). Role of PDGF-A expression in the control of vascular smooth muscle cell growth by transforming growth factor-B. J. Cell Biol. 111, 239-247.
115. Majesky M.W., Schwartz S.M., Clowes M.M. and Clowes A.W. (1987). Heparin regulates smooth muscle S phase entry in the injured rat carotid artery. Circ. Res. 61, 296-300.
116. Majesky M.W., Benditt E.P. and Schwartz S.M. (1988). Expression and developmental control of platelet-derived growth factor A-chain and B-chain/Sis genes in rat aortic smooth muscle cells. Proc. Natl. Acad. Sci. USA 85, 1524-1528.
117. Mann M., Gibbons G.H., Kernoff R.S., Diet F.P., Tsao P.S., Cooke J.P., Kaneda Y. and Dzau V.J. (1995). Genetic engineering of vein grafts resistant to atherosclerosis. Proc. Natl. Acad. Sci. USA 92, 4502-4506.
118. Marin J. (1995). Age-related changes in vascular responses: a review. Mech. Ageing Dev. 79, 71-114.
119. Mayol X. and Graña X. (1998). The p130 pocket protein: keeping order at cell cycle exit/re-entrance transitions. Front. Biosci. 3, 11-24.
120. McCaffrey T.A., Nicholson A.C., Szabo P.E., Weksler M.E. and Weksler B.B. (1988). Aging and atherosclerosis. The increased proliferation of arterial smooth muscle cells isolated from old rats is associated with increased platelet-derived growth factor-like activity. J. Exp. Med. 167, 163-174.
121. McCaffrey T.A. and Falcone D.J. (1993). Evidence for an age-related dysfunction in the antiproliferative response to transforming growth factor-beta in vascular smooth muscle cells. Mol. Biol. Cell. 4, 315-322.
122. McNamara D.B., Bedi B., Aurora H., Tena L., Ignarro L.J., Kadowitz P.J. and Akers D.L. (1993). L-arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem. Biophys. Res. Commun. 193, 291-296.
123. McPherson J., Sage H. and Bornstein P. (1981). Isolation and characterization of a glycoprotein secreted by aortic endothelial cells in culture: apparent identity with platelet thrombospondin. J. Biol. Chem 256, 11330-11336.
124. Miano J.M., Tota R.R., Vlasic N., Danishefsky K.J. and Stemerman M.B. (1990). Early proto-oncogene expression in rat aortic smooth muscle cells following endothelial removal. Am. J. Pathol. 137, 761-765.
125. Miano J.M., Vlasic N., Tota R.R. and Stemerman M.B. (1993). Localization of Fos and Jun proteins in rat aortic smooth muscle cells after vascular injury. Am. J. Pathol. 142, 715-724.
126. Mills I., Cohen C.R., Kamal K., Li G., Shin T., Du W. and Sumpio B.E. (1997). Strain activation of bovine aortic smooth muscle cell proliferation alignment: study of strain dependency and the role of protein kinase A and C signaling pathways. J. Cell Physiol. 170, 228-234.
127. Moncada S., Palmer R.M.J. and Higgs E.A. (1991). NO: physiology, pathophysiology and pharmacology. Pharmacol. Rev. 43, 109-142.
128. More R.S., Underwood M.J., Brack M.J., de Bono D.P. and Gershlick A.M. (1995). Changes in vessel wall plasminogen activator activity and smooth muscle cell proliferation and activation after arterial injury. Cardiovasc. Res. 29, 22-26.
129. Morgan D.O. (1995). Principles of CDK regulation. Nature 374, 131-134.
130. Morishita R., Gibbons G.H., Ellison K.E., Nakajima M., Zhang L., Kaneda Y., Ogihara T. and Dzau V.J. (1993). Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA 90, 8474-8478.
131. Morishita R., Gibbons G.H., Ellison K.E., Nakajima M., von der Leyen H., Zhang L., Kaneda Y., Ogihara T. and Dzau V.J. (1994a). Intimal hyperplasia after vascular injury is inhibited by antisense cdk2 kinase oligonucleotides. J. Clin. Invest. 93, 1458-1464.
132. Morishita R., Gibbons G.H., Kaneda Y., Ogihara T. and Dzau V.J. (1994b). Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene 149, 13-19.
133. Morishita R., Gibbons G.H., Horiuchi M., Ellison K.E., Nakajima M., Zhang L., Kaneda Y., Ogihara T. and Dzau V.J. (1995). A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle cell proliferation in vivo. Proc. Natl. Acad. Sci. USA 92, 5855-5859.
134. Moroi M., Zhang L., Yasuda T., Virmani R., Gold H.K., Fishman M.C. and Huang P.L. (1998). Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J. Clin. Invest. 101, 1225-1232.
135. Motokura T. and Arnold A. (1993). Cyclins and oncogenesis. Biochim. Biophys. Acta 1155, 63-78.
136. Mumby S.M., Abbott Brown D., Raugi D. and Bornstein P. (1984). Regulation of thrombospondin secretion by cells in culture. J. Cell. Physiol. 120, 280-288.
137. Nabel E.G., Yang Z., Liptay S., San H., Gordon D., Haudenschild C.C. and Nabel G.J. (1993a). Recombinant platelet-derived growth factor B gene expression in porcine arteries induces intimal hyperplasia in vivo. J. Clin. Invest. 91, 1822-1829.
138. Nabel E.G., Yang Z., Plautz G., Forough R., Zhan X., Haudenschild C.C., Maciag T. and Nabel G.J. (1993b). Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature 362, 844-846.
139. Nava E., Noll G. and Lüscher T.F. (1995). Nitric oxide in cardiovascular disease. Ann. Med. 27, 343-351.
140. Noda-Heiny H. and Sobel B.E. (1995). Vascular smooth muscle cell migration mediated by thrombin and urokinase receptor. Am. J. Physiol. 268, C1195-1201.
141. Noda-Heiny H., Daugherty A. and Sobel B.E. (1995). Augmented urokinase receptor expression in atheroma. Arterioscler. Thromb. Vasc. Biol. 15, 37-43.
142. Nurse P. (1994). Ordering S phase and M phase in the cell cycle. Cell 79, 547-550.
143. Ohno T., Gordon D., San H., Pompili V.J., Imperiale M.J., Nabel G.J. and Nabel E.G. (1994). Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 265, 781-784.
144. Okada S.S., Grobmyer S.R. and Barnathan E.S. (1996). Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion. Arterioscler. Thromb. Vasc. Biol. 16, 1269-76.
145. O'Shea K.S. and Dixit V.M. (1988). Unique distribution of extracellular matrix component thrombospondin in the developing mouse embryo. J. Cell Biol. 101, 2737-2748.
146. Panda D., Kundu G.C., Lee B.I., Peri A., Fohl D., Chackalaparampil I., Mukherjee B.B., Li X.D., Mukherjee D.C., Seides S., Rosenberg J., Stark K. and Mukherjee A.B. (1997). Potential roles of osteopontin and alphaVbeta3 integrin in the development of coronary artery restenosis after angioplasty. Proc. Natl. Acad. Sci. USA 94, 9308-9313.
147. Parkes J.L., Cardell R.R., Hubbard F.C., Hubbard D., Meltzer A. and Penn A. (1991). Cultured human atherosclerotic plaque smooth muscle cells retain transforming potential and display enhanced expression of the myc protooncogene. Am. J. Pathol. 138, 765-775.
148. Peeper D.S., van der Eb A.J. and Zantema A. (1994). The G1/S cell-cycle checkpoint in eukaryotic cells. Biochim. Biophys. Acta 1198, 215-230.
149. Peeper D.S., Upton T.M., Ladha M.H., Neuman E., Zalvide J., Bernards R., DeCaprio J.A. and Ewen M.E. (1997). Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 386, 177-181.
150. Peter M. and Herskowitz I. (1994). Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 79, 181-184.
151. Popma J.J., Califf R.M. and Topol E.J. (1991). Clinical trials of restenosis after coronary angioplasty. Circulation 84, 1426-1436.
152. Post M.J., Borst C. and Kuntz R.E. (1994). The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty. A study in the normal rabbit and the hypercholesterolemic yucatan micropig. Circulation 89, 2861-2821.
153. Predel H.-G., Yang Z., von Segesser L., Turina M., Bühler F.R. and Lüscher T.F. (1992). Implications of pulsatile stretch on growth of saphenous vein and mammary artery smooth muscle cells. Lancet 340, 878-879.
154. Pukac L.A., Castellot J.J. Jr., Wright, T.C. Jr., Caleb B.L. and Karnovsky M.J. (1990). Heparin inhibits c-fos and c-myc mRNA expression in vascular smooth muscle cells. Cell Regul. 1, 435-443.
155. Pyles J.M., March K.L., Mehdi K., Wilenski R.L. and Adam L.P. (1997). Activation of MAP Kinase in vivo follows balloon overstretch injury of porcine coronary and carotid arteries. Circ. Res. 81, 904-910.
156. Raghunath P.N., Tomaszewski J.E., Brady S.T., Caron R.J., Okada S.S. and Barnathan E.S. (1995). Plasminogen activator system in human coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 15, 1432-1443.
157. Raines E.W., Dower S.K. and Ross R. (1989). IL-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science 243, 393-396.
158. Raugi G.J., Mullen J.S., Barb D.H., Okada T. and Mayberg M.R. (1990). Thrombospondin deposition in rat carotid artery injury. Am. J. Pathol. 137, 179-185.
159. Reed M.J., Iruela-Arispe L., O'Brien E.R., Truong T., LaBell T., Bornstein P. and Sage E.H. (1995). Expression of thrombospondins by endothelial cells. Injury is correlated with TSP-1. Am. J. Pathol. 147, 1068-1080.
160. Reidy M.A., Irvin C. and Lindner V. (1996). Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries. Circ. Res. 78, 405-414.
161. Reilly C.F., Kindy M.S., Brown K.E., Rosenberg R.D. and Sonenshein G.E. (1989). Heparin prevents vascular smooth muscle cell progression through the G1 phase of the cell cycle. J. Biol. Chem. 264, 6990-6995.
162. Rivard A., Principe N. and Andrés V. (2000). Age-dependent increase in c-fos activity and cyclin A expression in vascular smooth muscle cells. A potential link between aging, smooth muscle cell proliferation and atherosclerosis. Cardiovasc. Res. (in press).
163. Rodés J., Côté G., Lespérance J., Bourassa M.G., Doucet S., Bilodeau L., Bertrand O.F., Harel F., Gallo R. and Tardif J.-C. (1998). Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation 97, 429-436.
164. Ross R. (1993). The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362, 801-809.
165. Roth J.J., Gahtan V., Brown J.L., Gerhard C., Swami V.K., Rothman V.L., Tulenko T.N. and Tuszynski G.P. (1998). Thrombospondin-1 is elevated with both intimal hyperplasia and hypercholesterolemia. J. Surg. Res. 74, 11-16.
166. Rothman A., Woler B., Button D. and Taylor P. (1994). Immediate-early gene expression in respose to hypertrophic and proliferative stimuli in pulmonary arterial smooth muscle cells. J. Biol. Chem. 269, 6399-6404.
167. Rudic R.D., Shesely E.G., Maeda N., Smithies O., Segal S.S. and Sessa W.C. (1998). Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J. Clin. Invest. 101, 731-736.
168. Salhany K.E., Robinson-Benion C., Candia A.F., Pledger W.J. and Holt J.T. (1992). Differential induction of the c-fos promoter through distinct PDGF receptor-mediated signaling pathways. J. Cell. Physiol. 150, 386-395.
169. Schneider J.E., Berk B.C., Gravanis M.B., Santoian E.C., Cipolla G.D., Tarazona N., Lassegue B. and King S.B. III (1993). Probucol decreases neointimal formation in a swine model of coronary artery balloon injury. A possible role for antioxidants in restenosis. Circulation 88, 628-637.
170. Schwartz R.S., Holmes D.R. and Topol E.J. (1992). The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J. Am. Coll. Cardiol. 20, 1284-1293.
171. Schwarzacher S.P., Lim T.T., Wang B., Kernoff R.S., Neibauer J., Cooke J.P. and Yeung A.C. (1997). Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty. Circulation 95, 1863-1869.
172. Serruys P., de Jaegere P., Kiemeneij F., Macaya C., Rutsch W., Heyndrickx G., Emanuelsson H., Marco J., Legrand V., Materne P., Belardi J., Sigwart U., Colombo A., Goy J.J., vand den Heuvel P., Delcan J., Morel M.-A., for the Benescent Study Group (1994). A comparison of balloon expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N. Engl. J. Med. 331, 489-495.
173. Shears L.L. II, Kawaharada N., Tzeng E., Billiar T.R., Watkins S.C., Kovesdi I., Lizonova A. and Pham S.M. (1997). Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J. Clin. Invest. 100, 2035-2042.
174. Shears L.L. II, Kibbe M.R., Murdock A.D., Billiar T.R., Lizonova A., Kovesdi I., Watkins S.C. and Tzeng E. (1998). Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J. Am. Coll. Surg. 187, 295-306.
175. Sherr C.J. (1994). G1 phase progression: cycling on cue. Cell 79, 551-555.
176. Shi Y., Hutchinson H.G., Hall D.J. and Zalewski A. (1993). Downregulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells. Circulation 88, 1190-1195.
177. Shi Y., Dodge G.R., Hall D.J., Desrochers P.E., Fard A., Shaheen F., Talbot C., Yurgenev L. and Zalewski A. (1994a). Inhibition of type 1 collagen synthesis in vascular smooth muscle cells by c-myc antisense oligomers. Circulation 90, 1-147.
178. Shi Y., Fard A., Galeo A., Hutchinson H.G., Vermani P., Dodge G.R., Hall D.J., Shaheen F. and Zalewski A. (1994b). Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation 90, 944-951.
179. Simari R.D., San H., Rekhter M., Ohno T., Gordon D., Nabel G.J. and Nabel E.G. (1996). Regulation of celular proliferation and intimal formation following balloon injury in atherosclerotic rabbit arteries. J. Clin. Invest. 98, 225-235.
180. Simons M. and Rosenberg R.D. (1992). Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides supress smooth muscle cell proliferation in vitro. Circ. Res. 70, 835-843.
181. Simons M., Edelman E.R., DeKeyser J.-L., Langer R. and Rosenberg R.D. (1992). Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 359, 67-70.
182. Sirois M.G., Simons M. and Edelman E.R. (1997). Antisense oligonucleotide inhibition of PDGFR-ß receptor subunit expression directs suppression of intimal thickening. Circulation 95, 669-676.
183. Sjölund M., Rahm M., Claesson-Welsh L., Sejersen T., Heldin C.-H. and Thyberg J. (1990). Expression of PDGF α-and ß-receptors in rat arterial smooth muscle cells is phenotype and growth state dependent. Growth Factors 3, 191-203.
184. CIP1-mediated inhibition of cell proliferation by overexpression of the Gax homeodomain gene. Genes Dev. 11, 1674-1689.
185. Smith R.C., Wills K.N., Antelman D., Perlman H., Truong L.N., Krasinski K. and Walsh K. (1997b). Adenoviral constructs encoding phosphorylation-competent full-length and truncated forms of the human retinoblastoma protein inhibit myocyte proliferation and neointima formation. Circulation 96, 1899-1905.
186. Southgate K.M., Davies M., Booth R.F.G. and Newby A.C. (1992). Involvement of extracellular matrix degrading metalloproteinases in rabbit aortic smooth muscle cell proliferation. Biochem. J. 288, 93-99.
187. Southgate K.M., Fisher M., Banning A.P., Thurston V.J., Baker A.M., Fabunmi R.P., Groves P.H., Davies M. and Newby A.C. (1996). Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid artery. Circ. Res. 79, 1177-1187.
188. Spagnoli L.G., Orlandi A., Mauriello A., De Angelis C. and Ramacci M.T. (1992). Age-dependent increase of rabbit aortic atherosclerosis. A morphometric approach. Pathol. Res. Pract. 188, 637-642.
189. Srivatsa S.S., Fitzpatrick L.A., Tsao P.W., Reilly T.M., Holmes D.R. Jr., Schwartz R.S. and Mousa S.A. (1997). Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation. Cardiovasc. Res. 36, 408-28.
190. Stadius M.L., Rowan R., Fleischhauer J.F., Kernoff R., Billingham M. and Gown A.M. (1992). Time course and cellular characteristics of the iliac artery response to acute balloon injury. An angiographic, morphometric, and immunocytochemical analysis in the cholesterol-fed New Zealand White rabbit. Arterioscl. Thromb. 12, 1267-1273.
191. Steg P.G., Tahlil O., Aubailly N., Caillaud J.-M., Dedieu J.-F., Berthelot K., Le Roux A., Feldman L., Perricaudet M., Denèfle P. and Branellec D. (1997). Reduction of restenosis after angioplasty in an atheromatous rabbit model by suicide gene therapy. Circulation 96, 408-411.
192. Stemerman M.B., Weinstein R., Rowe J.W., Maciag T., Fuhro R. and Gardner R. (1982). Vascular smooth muscle cell growth kinetics in vivo in aged rats. Proc. Natl. Acad. Sci. USA 79, 3863-3866.
193. Stouffer G.A., Hu Z., Sajid M., Li H., Jin G., Nakada M.T., Hanson S.R. and Runge M.S. (1998). Beta3 integrins are upregulated after vascular injury and modulate thrombospondin-and thrombin-induced proliferation of cultured smooth muscle cells. Circulation 97, 907-915.
194. Strauss B.H., Chisholm R.J., Keeley F.W., Gotlieb A.I., Logan R.A. and Armstrong P.W. (1994). Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circ. Res. 75, 650-658.
195. Sumpio B.E. and Banes A. (1988). Response of porcine aortic smooth muscle cells to cyclic tensional deformation in culture. J. Surg. Res. 44, 696-701.
196. Suzuki J.-I., Isobe M., Morishita R., Aoki M., Horie S., Okubo Y., Kaneda Y., Sawa Y., Matsuda H., Ogihara T. and Sekiguchi M. (1997). Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide. Nat. Med. 3, 900-903.
197. Sylvester A.M., Chen D., Krasinski K. and Andres V. (1998). Role of c-fos and E2F in the induction of cyclin A transcription and vascular smooth muscle cell proliferation. J. Clin. Invest. 101, 940-948.
198. Tanner F.C., Yang Z.-Y., Duckers E., Gordon D., Nabel G.J. and Nabel E.G. (1998). Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ. Res. 82, 396-403.
199. Taraboletti G., Roberts D., Liotta L.A. and Giavazzi R. (1990). Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J. Cell. Biol. 111, 765-772.
200. Tardif J.-C., Côté G., Lespérance J., Bourassa M.J.L., Doucet S., Bilodeau L., Nattel S. and de Guise P. (1997). Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N. Engl. J. Med. 337, 365-372.
201. Teirstein P.S., Massullo V., Jani S., Popma J.J., Mintz G.S., Russo R.J., Schatz R.A., Guarneri E.M., Steuterman S., Morris N.B., Leon M.B. and Tripuranemi P. (1997). Catheter-based radiotherapy to inhinbit restenosis after coronary stenting. N. Engl. J. Med. 336, 1697-1703.
202. Teirstein P.S., Massullo V., Jani S., Russo R.J., Cloutier D.A., Schatz R.A., Guarneri E.M., Steuterman S., Sirkin K., Norman S. and Tripuraneni P. (1999). Two-year follow-up after catheter-based radiotherapy to inhibit coronary restenosis [see comments]. Circulation 99, 243-247.
203. Thyberg J. (1998). Phenotypic modulation of smooth muscle cells during formation of neointimal thickening following vascular injury. Histol. Histopathol. 13, 871-891.
204. Thyberg J., Hedin U., Sjölund M., Palmberg L. and Bottger B.A. (1990). Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis 10, 966-990.
205. Topol E.J., Califf R.M., Weisman H.F., Ellis S.G., Tcheng J.E., Worley S., Ivanhoe R., George B.S., Fintel D., Weston M., Sigmon K., Anderson K.M., Lee K.L., Willerson J.T., on behalf of the EPIC investigators (1994). Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 343, 881-886.
206. Tuszynski G.P., Rothman V.L., Murphy A., Siegler K. and Knudsen K.A. (1988). Thrombospondin promotes platelet aggregation. Blood 72, 109-115.
207. Ueno H., Masuda S., Snishio S., Li J.J., Yamamoto H. and Takeshita A. (1997a). Adenovirus-mediated transfer of cyclin-dependent kinase inhibitor-p21 suppresses neointimal formation in the balloon-injured rat carotid arteries in vivo. Ann. NY Acad. Sci. 811, 401-411.
208. Ueno H., Yamamoto H., Ito S.-i., Li J.-J. and Takeshita A. (1997b). Adenovirus-mediated transfer of a dominant-negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo. Arterioscler. Thromb. Vasc. Biol. 17, 898-904.
209. Van Belle E., Maillard L., Tio F.O. and Isner J.M. (1997). Accelerated endothelialization by local delivery of recombinant human vascular endothelial growth factor reduces in-stent intimal formation. Biochem. Byophis. Res. Commun. 235, 311-316.
210. Van Zanten G.H., de Graaf S., Slootweg P.J., Heijnen H.F.G., Connolly T.M., de Groot P.G. and Sixma J.J. (1994). Increased platelet deposition on atherosclerotic coronary arteries. J. Clin. Invest. 93, 615-632.
211. Varenne O., Pislaru S., Gillijns H., Van Pelt N., Gerard R.D., Zoldhelyi P., Van de Werf F., Collen D. and Janssens S.P. (1998). Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation 98, 919-926.
212. von der Leyen H.E., Gibbons G.H., Morishita R., Lewis N.P., Zhang L., Nakajima M., Kaneda Y., Cooke J.P. and Dzau V.J. (1995). Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene. Proc. Natl. Acad. Sci. USA 92, 1137-1141.
213. Waga S., Hannon G.J., Beach D. and Stillman B. (1994). The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interacting with PCNA. Nature 369, 574-577.
214. Waksman R. (1997). Response to radiation therapy in animal restenosis models. Semin. Intervent. Cardiol. 2, 95-101.
215. Wei G.L., Krasinski K., Kearney M., Isner J.M., Walsh K. and Andrés V. (1997). Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Circ. Res. 80, 418-426.
216. Weinberg R.A. (1995). The retinoblastoma protein and cell cycle control. Cell 81, 323-330.
217. Weir L., Chen D., Pastore C., Isner J.M. and Walsh K. (1995). Expression of GAX, a growth-arrest homeobox gene, is rapidly down-regulated in the rat carotid artery during the proliferative response to balloon injury. J. Biol. Chem. 270, 5457-5461.
218. Wight T.N., Raugi G.J., Mumby S.M. and Bornstein P. (1985). Light microscopic immunolocation of thrombospondin in human tissues. J. Histochem. Cytochem. 33, 295-302.
219. Wilensky R.L., March K.L., Gradus-Pizlo I., Sandusky G., Fineberg N. and Hathaway D.R. (1995). Vascular injury, repair, and restenosis after percutaneous transluminal angioplasty in the atherosclerotic rabbit. Circulation 92, 2995-3005.
220. Wilson E., Mai Q., Sudhir K., Weiss R.H. and Ives H.E. (1993). Mechanical strain induces growth of vascular smooth muscle cells via autocrine action of PDGF. J. Cell Biol. 123, 741-747.
221. Winston J.T., Coats S.R., Wang Y.-Z. and Pledger W.J. (1996). Regulation of the cell cycle machinery by oncogenic ras. Oncogene 12, 127-134.
222. Yabkowitz R.Y., Mansfield P.J., Ryan U.S. and Suchard S.J. (1993). Thrombospondin mediates migration and potentiates platelet-derived growth factor-dependent migration of calf pulmonary artery smooth muscle cells. J. Cell. Physiol. 157, 24-32.
223. Yan Z.-Q. and Hansson G.K. (1998). Overexpression of inducible nitric oxide synthase by neointimal smooth muscle cells. Circ. Res. 82, 21-29.
224. Yang Z.-Y., Simari R.D., Perkins N.D., San H., Gordon D., Nabel G.J. and Nabel E.G. (1996). Role of p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc. Natl. Acad. Sci. USA 93, 7905-7910.
225. Yokoi H., Daida H., Kuwabara Y., Nishikawa H., Seki A., Kato K., Nishimura S., Kanoh T. and Yamaguchi H. (1997). Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the probucol angioplasty restenosis trial. J. Am. Coll. Cardiol. 30, 855-862.
226. Yonemitsu Y., Kaneda Y., Tanaka S., Nakashima Y., Komori K., Sugimachi K. and Sueishi K. (1998). Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. Circ. Res. 82, 147-156.
227. Zempo N., Kenagy R.D., Au T., Bendeck M., Clowes M.M., Reidy M.A. and Clowes A.W. (1994). Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J. Vasc. Surg. 20, 209-217.
228. Zempo N., Koyama M., Kenagy R.D., Lea H.J. and Clowes A.W. (1996). Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler. Throm. Vasc. Biol. 16, 28-33.
229. Zhu N.L., Wu L., Liu P.X., Gordon E.M., Anderson W.F., Starnes V.A. and Hall F.L. (1997). Downregulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation. Circulation 96, 628-635.
230. Zou X., Rudchenko S., Wong K.-K. and Calame K. (1997). Induction of c-myc transcription by the v-Abl tyrosine kinase requires Ras, Raf1, and cyclin-dependent kinases. Genes Dev. 11, 654-662.